6978 — Immunotech Biopharm Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$1.67bn
- HK$1.97bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -109 | -439 | -355 | -321 | -335 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -0.665 | 191 | 59.9 | 51 | 106 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 3.31 | -29.3 | 19.1 | 45.1 | 12.3 |
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -95.5 | -264 | -255 | -181 | -164 |
Capital Expenditures | -21 | -75.7 | -181 | -96.6 | -22.5 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 46.8 | -128 | -147 | 120 | -94.1 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 25.7 | -204 | -328 | 23.4 | -117 |
Financing Cash Flow Items | 44.2 | -77.9 | -3.68 | -19.6 | -8.52 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 217 | 1,055 | -11 | -36.1 | 274 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 154 | 563 | -594 | -193 | -6.29 |